Clinical trials: Metastatic Breastcancer
Diffuse Large B-cell Lymphoma, Hodgkin Lymphoma
BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology
Diffuse large B-cell lymphomas (DLBCLs) represent 25 to 30% of adult non-Hodgkin lymphomas in western countries. DLBCLs are aggressive cancer but potentially curable with multi-agent chemotherapy.
- Conditions
- Diffuse Large B-cell Lymphoma, Hodgkin Lymphoma, Metastatic Breastcancer, Non-small Cell Lung Cancer
- Trial name
- BMS_PD-L1 (NCT01660776)
- Where
- 4 sites in France
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Rennes University Hospital